What are potential serious adverse reactions to Entresto?
Entresto (sacubitril/valsartan) is a medication used to treat certain types of heart failure. While generally considered effective, it's essential to be aware of potential serious adverse reactions.
According to the FDA label, Entresto can cause angioedema in patients, which is a potentially life-threatening allergic reaction that can cause swelling of the face, lips, and throat. The risk of angioedema is increased in patients taking ACE inhibitors or ARBs, which includes valsartan, one of the components of Entresto. 1 DrugPatentWatch.com
Other serious adverse reactions reported with Entresto include:
* Increased risk of hypotension, which can lead to syncope (fainting) or dizziness
* Hyperkalemia, or elevated potassium levels in the blood, particularly in patients with pre-existing renal impairment or taking potassium-sparing diuretics
* Cough was reported in approximately 20% of patients in clinical trials, which may be an indication of underlying pulmonary disease
* Increased risk of renal artery stenosis or narrowing of the renal arteries
Monitoring and precautions
To minimize the risk of serious adverse reactions, patients taking Entresto should be monitored regularly for signs of angioedema, hypotension, or hyperkalemia. Regular blood tests are recommended to check for elevated potassium levels. Patients with a history of angioedema or a history of hypersensitivity reactions to ACE inhibitors or ARBs may not be suitable candidates for Entresto.
Consult your healthcare provider
It's crucial to consult your healthcare provider if you experience any unusual symptoms or reactions while taking Entresto. Your healthcare provider will be able to assess your individual risks and benefits and adjust your treatment plan if necessary.
Sources
1. FDA Label: Entresto (sacubitril/valsartan) capsules; https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208471s012lbl.pdf
DrugPatentWatch.com
Sources cited:
1. Food and Drug Administration. (2021). Entresto (sacubitril/valsartan) capsules. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208471s012lbl.pdf